View all news

Community Health Ventures Signs New Supplier Agreement With Masimo

07/23/2013
Contract Includes Pronto-7(R) and Pronto(R)

IRVINE, CA -- (Marketwired) -- 07/23/13 -- Masimo (NASDAQ: MASI) announced today that it has entered a new year-to-year group purchasing agreement with Community Health Ventures (CHV), the business development affiliate of the National Association of Community Health Centers (NACHC), representing more than 9,000 health centers nationwide. The new agreement allows CHV participants, at their discretion, to take advantage of special pricing and terms pre-negotiated by CHV for Masimo'sPronto-7(R) and Pronto(R).

The Pronto-7 and Pronto offer noninvasive and spot-check testing of total hemoglobin (SpHb), as well as SpO2, pulse rate (PR), and perfusion index (PI).

Both the Pronto-7 and Pronto will be available to CHV's U.S. customer base of community health centers, which serve the primary health care needs of more than 22 million people.

"We are extremely pleased to be partnered with Masimo, a leading developer of innovative technology to improve patient care and reduce cost of care. We're particularly excited to make health centers aware of Masimo's Pronto-7 and Pronto devices," said Gwen Siebert, Community Health Ventures Chief Operating Officer. "Health centers are recognized leaders in the provision of high quality primary care. This is due in large part to health centers using cutting-edge technology to improve their practice and standard of care. We're happy to promote Masimo products through the National Association of Community Health Center's (NACHC) endorsed program, the Value in Purchasing (ViP) program, and look forward to introducing health centers to these exciting, noninvasive innovations in patient care."

Jon Coleman, President, Worldwide Sales, Professional Services and Medical Affairs, stated, "We are happy to partner with Community Health Ventures to support their health centers in advancing care for their patients with noninvasive spot-checking of total hemoglobin, SpO2, pulse rate, and perfusion index."

About Community Health Ventures
Community Health Ventures (CHV) is the business development affiliate of the National Association of Community Health Centers (NACHC), organized in 1971. Founded in 2000, CHV was created under the direction of health center leadership and tasked with creating workable solutions to the tremendous economic pressures facing today's health centers. By negotiating group-purchasing agreements, staffing solutions, lab agreements and more, CHV helps health centers reduce costs and remain competitive. CHV's dedicated staff and management have over 50 years of combined Community Health Center experience and ensure that our programs meet the specialized needs of health centers. For more information, please visit www.communityhealthventures.com.

About the National Association of Community Health Centers (NACHC)
Founded in 1970, the National Association of Community Health Centers (NACHC) is a non-profit organization whose mission is to enhance and expand access to quality, community-responsive health care for America's medically underserved and uninsured. NACHC represents the nation's network of over 1,200 Federally Qualified Health Centers (FQHCs), which serve over 20 million people through over 8,000 sites located in all of the 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and Guam. For more information, please visit www.nachc.org

About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry™, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to the factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.

Media Contact:
Mike Drummond
Masimo Corporation
Phone: (949) 297-7434
Email: mdrummond@masimo.com

Source: Masimo

Multimedia Files:

Categories: Press Releases
View all news